SLC5A2 and type 2 diabetes mellitus: Five prospective RCTs, involving 46,969 participants, on SGLT2 inhibitors with stroke events as the primary endpoint in T2DM patients were subjected to the study (EMPA-REG, CANVAS, DECLARE-TIMI 58, CREDENCE, and VERTIS CV).